<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>75(5)</volume><submitter>Hahn M</submitter><pubmed_abstract>&lt;b>Aims:&lt;/b> Laparoscopic myomectomy (LM) has been the gold standard treatment for uterine fibroids in women desiring uterine conservation. To evaluate a new fibroid treatment modality - radiofrequency volumetric thermal ablation (RFVTA) - we compare 12-month results in women who had symptomatic uterine fibroids and who were randomized to laparoscopic ultrasound-guided RFVTA or LM. &lt;b>Materials and Methods:&lt;/b> Our study is a 1 : 1 parallel, randomized, prospective, single-center, longitudinal, comparative analysis of RFVTA to LM for fibroid treatment in women ≥ 18 years of age who desired uterine conservation. Fifty women were randomized intraoperatively to RFVTA (n = 25) or to LM (n = 25) after laparoscopic ultrasound mapping of the uterus. &lt;b>Results:&lt;/b> Post surgery, ablation and myomectomy subjects took pain medications for 4 days (range: 1-46) and 7 days (range: 1-83 days) respectively (p = 0.60). Ablation and myomectomy subjects missed 10.0 workdays (range: 2-86 days) and 17.0 workdays (range: 7-30 days) (p = 0.28), resumed normal activities in 20.5 days (range: 5-103 days) versus 28.0 days (range: 10-42 days) (p = 0.86) respectively. Mean symptom severity scores decreased (improved) by - 7.8 for the ablation subjects and by - 17.9 for the myomectomy subjects (p = 0.16). Health-related quality of life improved (increased) by 7.5 and 13.1, respectively, for the two groups (p = 0.46). Two myomectomy subjects had pregnancies that ended in a Cesarean delivery and a vaginal delivery of healthy infants. Two pregnancies in the RFVTA group ended in full-term vaginal deliveries of healthy infants. &lt;b>Conclusions:&lt;/b> Early postoperative recovery and twelve-month results attest to similar clinical benefits from RFVTA and LM.</pubmed_abstract><journal>Geburtshilfe und Frauenheilkunde</journal><pagination>442-449</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4461677</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial.</pubmed_title><pmcid>PMC4461677</pmcid><pubmed_authors>Wallwiener CW</pubmed_authors><pubmed_authors>Kramer B</pubmed_authors><pubmed_authors>Hahn M</pubmed_authors><pubmed_authors>Taran FA</pubmed_authors><pubmed_authors>Brucker S</pubmed_authors><pubmed_authors>Kraemer D</pubmed_authors><pubmed_authors>Wallwiener M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial.</name><description>&lt;b>Aims:&lt;/b> Laparoscopic myomectomy (LM) has been the gold standard treatment for uterine fibroids in women desiring uterine conservation. To evaluate a new fibroid treatment modality - radiofrequency volumetric thermal ablation (RFVTA) - we compare 12-month results in women who had symptomatic uterine fibroids and who were randomized to laparoscopic ultrasound-guided RFVTA or LM. &lt;b>Materials and Methods:&lt;/b> Our study is a 1 : 1 parallel, randomized, prospective, single-center, longitudinal, comparative analysis of RFVTA to LM for fibroid treatment in women ≥ 18 years of age who desired uterine conservation. Fifty women were randomized intraoperatively to RFVTA (n = 25) or to LM (n = 25) after laparoscopic ultrasound mapping of the uterus. &lt;b>Results:&lt;/b> Post surgery, ablation and myomectomy subjects took pain medications for 4 days (range: 1-46) and 7 days (range: 1-83 days) respectively (p = 0.60). Ablation and myomectomy subjects missed 10.0 workdays (range: 2-86 days) and 17.0 workdays (range: 7-30 days) (p = 0.28), resumed normal activities in 20.5 days (range: 5-103 days) versus 28.0 days (range: 10-42 days) (p = 0.86) respectively. Mean symptom severity scores decreased (improved) by - 7.8 for the ablation subjects and by - 17.9 for the myomectomy subjects (p = 0.16). Health-related quality of life improved (increased) by 7.5 and 13.1, respectively, for the two groups (p = 0.46). Two myomectomy subjects had pregnancies that ended in a Cesarean delivery and a vaginal delivery of healthy infants. Two pregnancies in the RFVTA group ended in full-term vaginal deliveries of healthy infants. &lt;b>Conclusions:&lt;/b> Early postoperative recovery and twelve-month results attest to similar clinical benefits from RFVTA and LM.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 May</publication><modification>2024-10-14T14:46:21.362Z</modification><creation>2019-03-27T01:53:11Z</creation></dates><accession>S-EPMC4461677</accession><cross_references><pubmed>26097247</pubmed><doi>10.1055/s-0035-1545931</doi></cross_references></HashMap>